Bristol-Myers Squibb has picked up its second “breakthrough” drug designation for a daclatasvir-based, all-oral combo for hepatitis C from the FDA, potentially shaving some regulatory time off its late-stage program as developers scramble to hijack market share from Gilead’s pioneering approach.

…read more

Source: Bristol-Myers picks up another ‘breakthrough’ trophy in hep C cocktail showdown


0 No comments